论文部分内容阅读
目的:研究参附注射液与注射用单唾液酸四己糖神经节苷脂钠治疗新生儿缺氧缺血性脑病(HIE)的临床疗效,为HIE治疗提供新的选择。方法:将符合入组标准的91例足月HIE患儿随机分为治疗组31例、对照组A 30例和对照组B 30例,对照组A在常规治疗基础上联合注射用单唾液酸四己糖神经节苷脂钠,对照组B在常规治疗基础上联合参附注射液治疗,治疗组在常规治疗的基础上同时联合参附注射液与注射用单唾液酸四己糖神经节苷脂钠治疗,观察患儿治疗症状改善的情况,同时进行新生儿神经行为评分(NBNA)评分,进行三组临床疗效的观察。结果:①治疗组患儿各项神经系统症状和体征指标消失时间均短于对照组A、B,差异亦存在显著性(p<0.05)。②治疗组的总有效率、显效率均高于对照组A、B,两者差异存在显著性,差异均具有统计学意义(p<0.05)。③治疗前治疗组与对照组(NBNA)评分差异不明显,具有可比性,治疗后7天和14天治疗组(NBNA)评分明显高于对照组A、B,差异亦存在显著性(p<0.05)。结论:参附注射液与注射用单唾液酸四己糖神经节苷脂钠能缩短神经损伤修复时间,加快症状改善速度,能够优化HIE现有治疗方案。
Objective: To study the clinical curative effect of Shenfu injection and monosialotetrahexosyl ganglioside sodium for neonatal hypoxic-ischemic encephalopathy (HIE), and to provide a new choice for the treatment of HIE. Methods: Ninety-one full-term HIE infants who met the inclusion criteria were randomly divided into treatment group (31 cases), control group (A30) and control group (B), control group (A) The control group B was treated with Shenfu injection on the basis of routine treatment. The treatment group was treated with Shenfu injection and monosialotetrahexosyl ganglioside Sodium treatment was used to observe the improvement of children’s symptoms. At the same time, Neonatal Behavioral Neurological Behavior Score (NBNA) was scored and the clinical efficacy of the three groups was observed. Results: ① The disappearance time of neurological symptoms and signs of children in treatment group were shorter than those in control group A and B (P <0.05). ② The total effective rate and markedly effective rate of the treatment group were higher than those of the control group A and B, there was significant difference between the two groups (p <0.05). ③ Before treatment, there was no significant difference between the NBNA score and the control group (NBNA), the scores of NBNA in 7 days and 14 days after treatment were significantly higher than those in control group A and B (P < 0.05). Conclusion: Shenfu injection and sodium monosialotetrahexosyl ganglioside can shorten the time of nerve injury repair, speed up the improvement of symptoms, and can optimize the existing treatment of HIE.